“Executive Summary: The antiparasitic medicine ivermectin, which is widely available in LMICs [low- and middle-income countries], has been tested in numerous clinical trials of prevention and treatment of covid-19 with promising results. A large body of evidence on ivermectin use in covid-19 had thus accumulated, which required urgent review by health professionals and other stakeholders to determine whether it could inform clinical practice in the UK and elsewhere. More specifically, answers were needed to the following priority questions: (i) For people with covid-19 infection, does ivermectin compared with placebo or no ivermectin improve health outcomes?, and (ii) for people at higher risk of covid-19 infection, does ivermectin compared with placebo or no ivermectin improve health outcomes?
On the 20th of February 2021, the British Ivermectin Recommendation Development (BIRD) meeting was convened in Bath, United Kingdom, to evaluate the evidence on ivermectin use for the prevention and treatment of covid-19. Evidence to address the priority questions was evaluated by a panel of clinical experts and other stakeholders in the form of a DECIDE evidence-to-decision framework, the gold standard tool for developing clinical practice guidelines…
The British Ivermectin Recommendation Development panel recommends ivermectin for the prevention and treatment of covid-19 to reduce morbidity and mortality associated with covid-19 infection and to prevent covid-19 infection among those at higher risk.”
Supporters and endorsements: https://bird-group.org/who-are-bird/